Rob Hershberg, HilleVax CEO
August 15, 2023 07:11 AM EDTUpdated 01:16 PM
R&D

Take­da spin­out Hill­e­Vax de­lays PhI­Ib norovirus topline da­ta un­til mid-2024 over pro­cess­ing lo­gis­tics

Katherine Lewin

News Reporter

Take­da spin­out Hill­e­Vax has de­layed topline da­ta from its Phase IIb norovirus vac­cine tri­al un­til mid-2024, the com­pa­ny an­nounced Mon­day in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times